Logo Logo
Group by: Item Type | Date
Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2017
Number of items: 6.

2023

Pott, Christiane ORCID logoORCID: https://orcid.org/0009-0005-9260-8340; Jurinovic, Vindi; Trotman, Judith ORCID logoORCID: https://orcid.org/0000-0001-8009-4593; Kehden, Britta; Unterhalt, Michael; Herold, Michael ORCID logoORCID: https://orcid.org/0000-0002-6801-3292; Jagt, Richard van der ORCID logoORCID: https://orcid.org/0000-0001-5706-0109; Janssens, Ann; Kneba, Michael; Mayer, Jiri ORCID logoORCID: https://orcid.org/0000-0003-0567-9887; Young, Moya; Schmidt, Christian; Knapp, Andrea; Nielsen, Tina; Brown, Helen ORCID logoORCID: https://orcid.org/0009-0007-3637-891X; Spielewoy, Nathalie; Harbron, Chris; Bottos, Alessia; Mundt, Kirsten; Marcus, Robert; Hiddemann, Wolfgang and Hoster, Eva ORCID logoORCID: https://orcid.org/0000-0002-0749-1389 (2023): Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma. A Prospective Analysis of the Phase III GALLIUM Study. In: Journal of Clinical Oncology [PDF, 794kB]

2022

Herold, Michael; Hoster, Eva ORCID logoORCID: https://orcid.org/0000-0002-0749-1389; Janssens, Ann; McCarthy, Helen; Tedeschi, Alessandra; Pocock, Chris; Rosta, Andras; Trněný, Marek; Nielsen, Tina G.; Knapp, Andrea; Hiddemann, Wolfgang and Marcus, Robert (2022): Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. In: HemaSphere, Vol. 6, No. 3, e699 [PDF, 558kB]

2021

Strefford, Jonathan C.; Nowicka, Malgorzata; Hargreaves, Chantal E.; Burton, Cathy; Davies, Andrew; Ganderton, Rosalind; Hiddemann, Wolfgang; Iriyama, Chisako; Klapper, Wolfram; Latham, Kate V.; Martelli, Maurizio; Mir, Farheen; Parker, Helen; Potter, Kathleen N.; Rose-Zerilli, Matthew J. J.; Sehn, Laurie H.; Trneny, Marek; Vitolo, Umberto; Bolen, Christopher R.; Klein, Christian; Knapp, Andrea; Oestergaard, Mikkel Z. and Cragg, Mark S. (2021): Single-nucleotide Fc gamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. In: Blood Advances, Vol. 5, No. 15: pp. 2935-2944

2020

Mir, Farheen; Mattiello, Federico; Grigg, Andrew; Herold, Michael; Hiddemann, Wolfgang; Marcus, Robert; Seymour, John F.; Bolen, Christopher R.; Knapp, Andrea; Nielsen, Tina and Casulo, Carla (2020): Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. In: American Journal of Hematology, Vol. 95, No. 12: pp. 1503-1510

2019

Klanova, Magdalena; Oestergaard, Mikkel Z.; Trneny, Marek; Hiddemann, Wolfgang; Marcus, Robert; Sehn, Laurie H.; Vitolo, Umberto; Bazeos, Alexandra; Goede, Valentin; Zeuner, Harald; Knapp, Andrea; Sahin, Deniz; Spielewoy, Nathalie; Bolen, Christopher R.; Cardona, Andres; Klein, Christian; Venstrom, Jeffrey M.; Nielsen, Tina and Fingerle-Rowson, Guenter (2019): Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. In: Clinical Cancer Research, Vol. 25, No. 15: pp. 4634-4643

2017

Grigg, Andrew; Dyer, Martin J. S.; Gonzalez Diaz, Marcos; Dreyling, Martin; Rule, Simon; Lei, Guiyuan; Knapp, Andrea; Wassner-Fritsch, Elisabeth and Marlton, Paula (2017): Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. In: Haematologica, Vol. 102, No. 4: pp. 765-772

This list was generated on Sun Jun 2 04:29:17 2024 CEST.